| abstract |
The invention generally relates to the use of nuclear transport modulators, e.g., XPO1 inhibitors, such as a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, as defined and described herein, in a method for treating liposarcoma in a subject in need thereof. |